Sipuleucel T- The Potential Arrival in the Field of Immunotherapy for Prostate Cancer

Teena Chhabra
Additional contact information
Teena Chhabra: ISF College Of Pharmacy, Moga, Punjab, India

Biomedical Journal of Scientific & Technical Research, 2023, vol. 52, issue 4, 44012-44022

Abstract: Sipuleucel-T represents a novel immunotherapeutic compound designed to stimulate an immune response against metastatic castration-resistant prostate cancer (mCRPC). It is a personalized therapeutic vaccine in which individual patient-specific immune cells are used. It works by focusing on prostate cancer by triggering the patient’s own immune system. There are three doses total in a typical sipuleucel-T therapy regimen.

Keywords: Journals on Medical Drug and Therapeutics; Journals on Emergency Medicine; Physical Medicine and Rehabilitation; Journals on Infectious Diseases Addiction Science and Clinical Pathology; Open Access Clinical and Medical Journal; Journals on Biomedical Science; List of Open Access Medical Journal; Journals on Biomedical Engineering; Open Access Medical Journal; Biomedical Science Articles; Journal of Scientific and Technical Research (search for similar items in EconPapers)
Date: 2023
References: Add references at CitEc
Citations:

Downloads: (external link)
https://biomedres.us/pdfs/BJSTR.MS.ID.008298.pdf (application/pdf)
https://biomedres.us/fulltexts/BJSTR.MS.ID.008298.php (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:abf:journl:v:52:y:2023:i:4:p:44012-44022

DOI: 10.26717/BJSTR.2023.52.008298

Access Statistics for this article

Biomedical Journal of Scientific & Technical Research is currently edited by Robert Thomas

More articles in Biomedical Journal of Scientific & Technical Research from Biomedical Research Network+, LLC
Bibliographic data for series maintained by Angela Roy ().